Skip to main content
رجوع
GNNSF logo

Genscript Biotech Corporation

جودة البيانات: 100%
GNNSF
OTC Healthcare Biotechnology
KWD 1.42
KWD 0.00 (0.00%)
القيمة السوقية: 3.10B
نطاق اليوم
KWD 1.42 KWD 1.50
نطاق 52 أسبوعًا
KWD 1.28 KWD 2.42
حجم التداول
600
متوسط 50 يوم / 200 يوم
KWD 1.71 / KWD 2.03
الإغلاق السابق
KWD 1.42

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E -5.8 0.4
P/B 0.8 2.9
ROE % -12.9 3.7
Net Margin % -55.5 3.8
Rev Growth 5Y % 17.1 10.0
D/E 0.1 0.2

النقاط الرئيسية

Revenue grew 17.10% annually over 5 years — strong growth
Earnings declined -118.02% over the past year
Debt/Equity of 0.13 — conservative balance sheet
Negative free cash flow of -72.27M
PEG of 0.06 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 44.54%

النمو

Revenue Growth (5Y)
17.10%
Revenue (1Y)61.64%
Earnings (1Y)-118.02%
FCF Growth (3Y)N/A

الجودة

Return on Equity
-12.89%
ROIC4.28%
Net Margin-55.53%
Op. Margin26.60%

الأمان

Debt / Equity
0.13
Current Ratio1.47
Interest Coverage14.76

التقييم

P/E Ratio
-5.81
P/B Ratio0.78
EV/EBITDA13.50
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 61.64% Revenue Growth (3Y) 6.99%
Earnings Growth (1Y) -118.02% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 17.10% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 960.95M Net Income (TTM) -533.62M
ROE -12.89% ROA -11.00%
Gross Margin 57.65% Operating Margin 26.60%
Net Margin -55.53% Free Cash Flow (TTM) -72.27M
ROIC 4.28% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.13 Current Ratio 1.47
Interest Coverage 14.76 Dividend Yield 0.00%
Valuation
P/E Ratio -5.81 P/B Ratio 0.78
P/S Ratio 3.23 PEG Ratio 0.06
EV/EBITDA 13.50 Dividend Yield 0.00%
Market Cap 3.10B Enterprise Value 3.45B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 960.95M 594.49M 839.53M 625.70M 511.06M
Net Income -533.62M 2.96B -95.48M -226.85M -358.71M
EPS (Diluted) -0.25 1.36 -0.05 -0.11 -0.18
Gross Profit 554.02M 272.13M 409.55M 304.08M 282.52M
Operating Income 255.62M 9.28M -415.79M -436.04M -368.31M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 4.85B 5.28B 3.39B 2.55B 2.23B
Total Liabilities 876.30M 954.91M 1.34B 1.18B 1.14B
Shareholders' Equity 3.96B 4.32B 1.39B 1.01B 1.05B
Total Debt 523.15M 170.57M 416.99M 349.80M 156.45M
Cash & Equivalents 173.59M 131.99M 1.45B 1.02B 1.18B
Current Assets 1.06B 834.98M 2.35B 1.76B 1.64B
Current Liabilities 720.08M 307.34M 494.81M 545.98M 464.37M

درجات الاستراتيجيات

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#125 of 146
27

النشاط الأخير

دخل Full Throttle
Mar 24, 2026